Excelra Blog

Data Science To Empower
Life Science Innovation

Latest Stories

Featured Stories

By
April 27, 2020

Remdesivir- Potential Drug Repurposing Candidate for COVID-19

Mechanism of Action: RNA-dependent RNA polymerase (RdRp) inhibition

Remdesivir, is an antiviral medication being developed by Gilead Sciences for the treatment for Ebola virus disease. Animal studies have found it to be active against SARS and MERS viruses. Post the outbreak of COVID-19 pandemic in China, Gilead began laboratory testing of Remdesivir against SARS-CoV-2 in January 2020. Currently, phase-3 clinical trials are underway for Remdesivir to treat COVID-19 patients. The pro-drug (Remdesivir) is metabolized to active molecule (GS-441524). GS-441524, is an adenosine nucleotide analog. Ebola virus studies have shown, Remdesivir inhibited the viral RNA-dependent RNA polymerase (RdRp) enzyme to stop viral genome replication and viral RNA production. Remdesivir is Highly selective for Ebola Virus RdRp as compared to human mitochondrial RNA polymerase. Thus, specific targeting of RdRp can be an effective way to neutralize the SARS-CoV-2 infection.

 

RdRp_v2

Excelra's open-access COVID-19 Drug Repurposing Database is a synoptic compilation of ‘Approved’ small molecules and biologics, which can rapidly enter either Phase 2 or 3, or may even be used directly in clinical settings against COVID-19. The database additionally includes information on promising drug candidates that are in various ‘clinical, pre-clinical and experimental’ stages of drug discovery and development.

 

Supported with referenced literature, we provide mechanistic insights into SARS-CoV-2 biology and disease pathogenesis. We hope that these drug repositioning approaches can help the global biotech and pharma community develop treatments to combat COVID-19.

 

Website: www.excelra.com

Email: marketing@excelra.com 

Subscribe for Updates

Request Meeting

Lorem Ipsum is a simple dummy text used as a dummy text contents. Lorem ipsum will be replaced. Lorem Ipsum is a simple dummy text used as a dummy text contents. Lorem ipsum will be replaced.Lorem Ipsum is a simple dummy text used as a dummy text contents. Lorem ipsum will be replaced.

Submit Comment

BUY On HUBSPOT